IP Library Granted Patent US 9,422,327
Granted Patent B2
US 9,422,327 · App. 10/549,631 · Granted Aug 23, 2016

Process for preparing crystalline ciclesonide with defined particle size

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,422,327
App. No.
10/549,631
Granted
Aug 23, 2016
Kind
B2
Abstract

The invention relates to a novel process for preparing crystalline ciclesonide with an advantageous particle size and to the use for producing pharmaceutical preparations, in particular for topical use. The crystalline ciclesonide obtained by the novel process has advantageous aerodynamic properties, and can be further processed to inhalable or nasally administered pharmaceutical preparations without further mechanical micronization.

Claims (28)

1. A process for preparing a compound of the formula I

in crystalline form, with defined particle size, comprising the steps of

a) preparing a solution of the compound of the formula I in a suitable water-miscible organic solvent;

b) adding the solution obtained in a) to water and

c) isolating a precipitate with a particle diameter for 50% of the total volume of all articles (X 50 ) of less than or equal to 3 μm of the compound of the formula I which is formed.

2. The process according to claim 1 , characterized in that the suitable water-miscible organic solvent is an alcohol.

3. The process according to claim 2 , characterized in that the alcohol is selected from the group consisting of methanol, ethanol, N-propanol, isopropanol and mixtures in any mixing ratio thereof.

4. The process according to claim 3 , characterized in that the alcohol is ethanol.

5. The process according to claim 1 , characterized in that the suitable water-miscible organic solvent is selected from the group consisting of acetone, tetrahydrofuran and dimethylformamide.

6. The process according to claim 1 , characterized in that the temperature of the suitable water-miscible organic solvent is in the range from 15° C. to 10° C. below the boiling point of the solvent.

7. The process according to claim 6 , characterized in that the temperature of the suitable water-miscible organic solvent corresponds to the room temperature at which the process is carried out.

8. The process according to claim 1 , characterized in that the temperature of the water is from 10 to 50° C.

9. The process according to claim 7 , characterized in that the temperature of the water corresponds to the room temperature at which the process is carried out.

10. The process according to claim 1 , characterized in that, in step (a), the compound of the formula I is substantially in the form of the R epimer.

11. The process according to claim 10 , characterized in that the proportion of R epimer in the compound of the formula I is more than 95%.

12. The process according to claim 10 , characterized in that the compound of the formula I is ciclesonide.

13. The process according to claim 1 , characterized in that the precipitate obtained in step c) is subsequently dried.

14. The process for preparing a compound of the formula I ng to claim 1 in crystalline form with defined particle size, comprising the steps of

a) preparing a compound of the formula I by acylation of a compound of the formula II

with a suitable acylating agent;

b) crystallizing the compound of the formula I obtained in a) by adding water to a solution of the compound in a suitable water-miscible organic solvent or heating a suspension of the compound of the formula I in a mixture of a suitable water-miscible organic solvent and water,

c) removing the resulting R epimer-enriched precipitate of the compound of the formula I from the water/solvent mixture;

d) if desired repeating step b);

e) preparing a solution of the compound obtained in c) in a suitable water-miscible organic solvent;

f) adding the solution obtained in e) to water and

g) isolating a precipitate with a particle diameter for 50% of the total volume of all particles (X 50 ) of less than or equal to 3 μm which has been formed of the compound of the formula I.

15. The process according to claim 1 , where the particle size is characterized by an X 50 in the range from 1.8 to 2.0.

16. The process according to claim 14 , where the organic solvents used in steps b) and e) are the same solvents.

Assignments (20)
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded May 27, 2025
From: COVIS PHARMA GBMH
To: HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 071409/0368 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Mar 17, 2025
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: COVIS PHARMA GMBH
Reel/Frame 070537/0122 →
RELEASE OF SECURITY INTEREST Recorded Jun 2, 2023
From: BARCLAYS BANK PLC
To: COVIS PHARMA GMBH
Reel/Frame 063841/0208 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY (SECOND LIEN) Recorded Feb 18, 2022
From: COVIS PHARMA GMBH
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 059232/0514 →
RELEASE OF SECURITY INTEREST Recorded Feb 18, 2022
From: CAPITAL ONE, NATIONAL ASSOCIATION
To: COVIS PHARMA B.V.
Reel/Frame 059043/0239 →
RELEASE OF SECURITY INTEREST Recorded Feb 18, 2022
From: CAPITAL ONE, NATIONAL ASSOCIATION
To: COVIS PHARMA GMBH
Reel/Frame 059043/0226 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY (FIRST LIEN) Recorded Jan 4, 2022
From: COVIS PHARMA GMBH
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 058640/0787 →
SECURITY INTEREST Recorded Feb 22, 2021
From: COVIS PHARMA GMBH
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 055354/0063 →
BUSINESS TRANSFER AND CONTRIBUTION AGREEMENT Recorded Dec 16, 2020
From: COVIS PHARMA B.V.
To: COVIS PHARMA GMBH
Reel/Frame 054793/0416 →
RELEASE OF SECURITY INTEREST Recorded Mar 17, 2020
From: CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: COVIS PHARMA B.V.
Reel/Frame 052142/0961 →
SECURITY INTEREST Recorded Mar 12, 2020
From: COVIS PHARMA B.V.
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 052095/0262 →
SECURITY INTEREST Recorded Dec 20, 2018
From: COVIS PHARMA B.V.
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 047834/0926 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2018
From: ASTRAZENECA AB
To: COVIS PHARMA B.V.
Reel/Frame 047761/0435 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2017
From: TAKEDA GMBH
To: ASTRAZENECA AB
Reel/Frame 041328/0362 →
CHANGE OF NAME Recorded Jul 29, 2015
From: NYCOMED GERMANY HOLDING GMBH
To: TAKEDA GMBH
Reel/Frame 036205/0179 →
MERGER Recorded Jul 28, 2015
From: TAKEDA GMBH
To: NYCOMED ASSET MANAGEMENT GMBH
Reel/Frame 036193/0224 →
MERGER Recorded Jul 28, 2015
From: NYCOMED ASSET MANAGEMENT GMBH
To: NYCOMED GERMANY HOLDING GMBH
Reel/Frame 036201/0478 →
CHANGE OF NAME Recorded Mar 26, 2013
From: NYCOMED GMBH
To: TAKEDA GMBH
Reel/Frame 030091/0737 →
CHANGE OF NAME Recorded Sep 4, 2007
From: ALTANA PHARMA AG
To: NYCOMED GMBH
Reel/Frame 019783/0625 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2005
From: SCHMIDT, BEATE
To: ALTANA PHARMA AG
Reel/Frame 016984/0259 →